Metformin and other biguanides in oncology: advancing the research agenda.
Retrospective studies that may be impractical to confirm prospectively suggest that diabetics treated with metformin have a substantially reduced cancer burden compared with other diabetics. It is unclear if this reflects a chemopreventive effect, an effect on transformed cells, or both. It also remains to be established if these data have relevance to people without diabetes. Laboratory models, however, provide independent impressive evidence for the activity of metformin and other biguanides in both cancer treatment and chemoprevention. Investigations of mechanisms of action of biguanides have revealed considerable complexity and have identified important gaps in knowledge that should be addressed to ensure the optimal design of clinical trials of these agents. Such trials may define important new indications for biguanides in the prevention and/or treatment of many common cancers.
Pollak
Michael
M
3755 Cote-Ste.-Catherine, Montreal, Quebec, Canada H3T 1E2. michael.pollak@mcgill.ca
D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D001645:Biguanides / Q000494:pharmacology / Q000627:therapeutic use*; D035843:Biomedical Research / Q000639:trends*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use; D008495:Medical Oncology / Q000639:trends*; D008687:Metformin / Q000494:pharmacology / Q000627:therapeutic use*; D009369:Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001645:Biguanides; D007004:Hypoglycemic Agents; D008687:Metformin
J Clin Invest. 2010 Jul;120(7):2355-69
20577053
Cancer Prev Res (Phila). 2010 Sep;3(9):1049-52
20810671
Mol Cell. 2008 Apr 25;30(2):214-26
18439900
JAMA. 2008 Jan 9;299(2):185-93
18182600
Nature. 2004 Apr 1;428(6982):569-74
15058305
Nat Rev Cancer. 2009 Aug;9(8):563-75
19629071
Diabetes Care. 2010 Jun;33(6):1304-8
20299480
Nature. 2009 Apr 9;458(7239):725-31
19279572
Breast Cancer Res Treat. 2010 Sep;123(2):333-44
20204498
Ann Intern Med. 2007 Sep 18;147(6):386-99
17638715
Cell Metab. 2006 Jun;3(6):403-16
16753576
J Clin Invest. 2007 May;117(5):1422-31
17476361
J Clin Endocrinol Metab. 2006 Apr;91(4):1305-8
16434464
Nat Rev Cancer. 2008 Dec;8(12):915-28
19029956
Bull Exp Biol Med. 2005 Jun;139(6):721-3
16224592
Mol Carcinog. 2010 Jul;49(7):662-71
20564343
Cancer Res. 2008 Dec 15;68(24):10238-46
19074892
Endocr Relat Cancer. 2010 Jun 01;17(2):351-60
20228137
Cancer Prev Res (Phila). 2008 Oct;1(5):369-75
19138981
Biochem J. 2008 Jun 1;412(2):211-21
18387000
Cancer Cell. 2004 Jul;6(1):91-9
15261145
Breast Cancer Res Treat. 2010 Aug;123(1):271-9
20135346
Endocr Rev. 2009 Feb;30(1):1-50
19056992
J Clin Oncol. 2009 Jul 10;27(20):3297-302
19487376
Cancer Res. 2006 Nov 1;66(21):10269-73
17062558
Cell Cycle. 2009 Jan 1;8(1):88-96
19106626
Nature. 2009 Jul 2;460(7251):103-7
19494812
Endocr Relat Cancer. 2008 Sep;15(3):833-9
18469156
Cancer Res. 2007 Jul 15;67(14):6745-52
17638885
Cancer Res. 2007 Nov 15;67(22):10804-12
18006825
N Engl J Med. 1996 Feb 29;334(9):574-9
8569826
Cell Metab. 2009 May;9(5):401-3
19416708
N Engl J Med. 2002 Feb 7;346(6):393-403
11832527
Antimicrob Agents Chemother. 2010 May;54(5):1965-72
20231400
Cell Metab. 2010 Jun 9;11(6):554-65
20519126
Cancer Res. 2009 Oct 1;69(19):7507-11
19752085
Diabetologia. 2010 Oct;53(10):2086-8
20645073
Cell Metab. 2005 Jan;1(1):15-25
16054041
Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3329-35
14985505
Prostate. 2009 Jan 1;69(1):33-40
18785179
Cancer Res. 2010 Mar 15;70(6):2465-75
20215500
Cancer Prev Res (Phila). 2010 Sep;3(9):1066-76
20810672
Science. 2005 Dec 9;310(5754):1642-6
16308421
Nature. 2010 Jun 24;465(7301):1005
20577188
Int J Radiat Oncol Biol Phys. 2010 Sep 1;78(1):221-9
20615625
J Biol Chem. 2000 Jan 7;275(1):223-8
10617608
CA Cancer J Clin. 2010 Jul-Aug;60(4):207-21
20554718